Question 1

What specific symptoms of schizophrenia prodrome does this treatment aim to address?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ethyl-EPA Treatment of Prodromal Patients clinical trial (NCT00634361). Contact the study team or your healthcare provider for specific answers.

Question 2

How does ethyl-eicosapentaenoic acid compare to other treatment options available?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ethyl-EPA Treatment of Prodromal Patients clinical trial (NCT00634361). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of taking this omega-3 fatty acid?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ethyl-EPA Treatment of Prodromal Patients clinical trial (NCT00634361). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in this trial, and what will my visits look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ethyl-EPA Treatment of Prodromal Patients clinical trial (NCT00634361). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the treatment period?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ethyl-EPA Treatment of Prodromal Patients clinical trial (NCT00634361). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any follow-up procedures after the trial ends?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Ethyl-EPA Treatment of Prodromal Patients clinical trial (NCT00634361). Contact the study team or your healthcare provider for specific answers.

What this study is about